• Hatchtech Pty. Ltd., of Melbourne, Australia, published data describing the mechanism of action of the active ingredient (Ha44) in its head lice product DeOvo. Read More
More than a year on from a controversial opinion from the Court of Justice of the European Union (CJEU) on the patentability of innovations derived from embryonic stem cell (ESC) research, Germany's Federal Court of Justice (Bundesgerichtshof) has provided a final decision in the case, which leaves some scope for patent grants in that field. Read More
A recent European licensing deal between Orphan Europe and Erytech Pharma SA on a novel formulation of asparaginase, called Graspa, is further evidence of the commercial revitalization of a long-established treatment in hematologic cancer. Read More
The third spin-off from the entrepreneurship partnership program (EPP) launched in April by Merck KGaA biopharmaceutical division Merck Serono SA in conjunction with the closure of its Geneva headquarters, Asceneuron SA is focusing on one of biotech's most elusive targets: Alzheimer's disease (AD). Read More
LONDON – Two major networks of genes and their encoded proteins, involved in lipid metabolism and inflammation, play an important role in determining a person's risk of developing coronary artery disease (CAD), a new study has found. Read More
Eporgen Venture SpA, an Italian early stage venture capital fund with a diversified investor base, has logged the first major transaction of its portfolio, the licensing of a therapeutic cancer vaccine program, GX301, from Genovax srl to Mediolanum Farmaceutici SpA. Read More
